bioAffinity Technologies, Inc. (BIAF) Form 8-K — Nov 6, 2026
bioAffinity Technologies reported Q3 2026 revenue of approximately $1.1 million, down about 26% from $1.4 million a year earlier, citing lower average reimbursement per CyPath Lung test and fewer cases at its PPLS laboratory. Net loss widened to $5.3 million from $5.1 million. Commercial momentum in CyPath Lung remains strong on volume: unit sales doubled year to date, testing revenue for the first nine months rose 79% to about $1.1 million, and ordering physicians grew 89% in the quarter. The company also signed a distribution deal with AvMEDICAL to reach VA and government healthcare markets.
Key figures
- Revenue
- 1070280
- Revenue Yoy
- -26.0%
- Total Assets
- 7553671
- Cash Position
- 2550034
- Shares Outstanding
- 1166625
- Q3 2025 revenue
- 1446066
- Us patents awarded
- 22
- Pending applications
- 36
- Operating expenses q3
- 4580952
- Nine month revenue 2025
- 4569146
- Nine month revenue 2026
- 3932386
- Ordering physicians growth
- 89%
- Cypath unit sales growth ytd
- 100%
- Cypath testing revenue ytd growth
- 79%
- Gross proceeds raised aug oct 2026
- $8.0 million
- Post quarter financing gross proceeds
- $4.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.